RESUMEN
In 2012, intramuscular midazolam appears as effective as intravenous lorezepam for the first line treatment of convulsive status epilepticus. Perampanel, a new anti-epileptic drug, will be soon available. Two oral treatments are now available for stroke prevention in atrial fibrillation setting. The methylphenidate and the Tai Chi could increase the walk capacity of patients suffering from Parkinson disease. A comprehensive cardiac work-up is essential for some congenital myopathy. A new drug against migraine seems free from vasoconstrictive effect. Antioxidants are harmful in Alzheimer disease. Some oral medication will be available for multiple sclerosis.
Asunto(s)
Neurología/tendencias , Anticonvulsivantes/uso terapéutico , Trastornos Cerebrovasculares/terapia , Demencia/terapia , Discinesias/terapia , Epilepsia/tratamiento farmacológico , Humanos , Trastornos Mentales/terapia , Neuroinmunomodulación/fisiología , Neurología/métodos , Enfermedades Neuromusculares/terapia , Terapias en Investigación/métodos , Terapias en Investigación/tendenciasRESUMEN
Twelve patients with a catastrophic reaction (CR) (an outburst of frustration, depression, and anger when confronted with a task) were identified in a prospective cohort population (n = 326) with first-ever stroke admitted within 48 hours from onset. The authors' findings suggest that CR is a rare though not exceptional phenomenon in acute stroke and is associated with nonfluent aphasias and left opercular lesions. CR, poststroke depression, and emotionalism are distinct but related disorders.